List of Contributors

Preface

PART 1 GENERAL ASPECTS

1.1 Classification and Diagnostics

Laura Fratiglioni

1.2 Epidemiology

Laura Fratiglioni

1.3 Symptomatology: Functional Capacity and Behaviour

Henry Brodaty and David Lie

1.4 Care Options and Service Innovations in Dementia Care

Lennarth Johansson

1.5 Different Ways of Organizing and Financing Health Care

Stefan Håkansson

1.6 Cultural Concepts of Care for the Demented

Bernard Ineichen

1.7 Interaction with People Suffering Severe Dementia

Astrid Norberg

1.8 Distress and Burden for Family Caregivers

Carol J. Whitlatch

PART 2 HEALTH ECONOMICS APPROACHES TO DEMENTIA

2.1 Principles of Pharmacoeconomics

Michael Drummond

2.2 Methodological Issues in Health Economic Studies of Dementia

Göran Karlsson, Bengt Jönsson, Anders Wimo and Bengt Winblad

2.3 Modeling Disease Progression with Markov Models

Frank A. Sonnenberg and Elaine A. Leventhal

2.4 Cost of illness of Dementia

Wendy Max

2.5 Costs of Dementia in the Netherlands

Marc A. Koopmanschap, Johan J. Polder, Willem J. Meerding, Luc Bonneux and Paul J. van der Maas

2.6 Cost of Treatment and Care of Alzheimer's Disease in Germany

J.-M. Graf v. d. Schulenburg, Ines Schulenburg, Rolf Horn, Hans-Jürgen Möller, Thomas Bernhardt, Andreas Grass and Oliver Mast

2.7 Costing Community Care of People with Dementia

Martin Knapp and Rachel Wigglesworth

2.8 Indirect Costs and Costing Informal Care

Marc A. Koopmanschap and Werner B.F. Brouwer

2.9 The Resident Assessment Instrument (RAI) and Resource Use in Dementia Care

Gunnar Ljunggren and John N. Morris

2.10 Costs of Diagnostic Procedures

Serge Gauthier

2.11 How Will Japan Cope with the Impending Surge of Dementia?

Yumiko Arai and Naoki Ikegami

2.12 Drug Costs in Dementia Care

Johan Fastbom and Maria Stella T. Giron

2.13 Costs of Dementia-Specific Care Approaches

Anders Wimo, Gunnar L. Junggren and Bengt Wipblad

PART 3 OUTCOME MEASUREMENTS

3.1 Test Scores in Clinical Trials vs Performance in Real Life: Can Clinical Global Assessments Bridge the Gap?

Rachelle Smith Doody

3.2 Severity Scales

Barry Reisberg, Emile Franssen, Liduin Souren, Sunnie Kenowski and Stefanie Auer

3.3 Measuring QALYs in Dementia

Peter J. Neumann, Richard C. Hermann and Milton C. Weinstein

3.4 Assessing ADLIIADL in Persons with Dementia

Louise Nygård

3.5 Assessment of Cognitive Functioning

Ove Almkvist

3.6 Measurements of Quality of Life in Dementia

Peter Whitehouse

3.7 Assessment of Behavioral and Psychiatric Symptoms in Patients with Dementia Disorders

Sture Eriksson and Anders Wimo

3.8 Instruments to Measure the Family Caregiver Burden

Margareta Grafström and P.O. Sandman

PART 4 PHARMACOECONOMIC ASPECTS

4.1 Drug Authorities' Policy on the Assessment of Drugs for Dementia

Suzanne Hill and Patricia McGettigan

4.2 Designing Phase III Trials of Anti-dementia Drugs with a View towards Pharmacoeconomic Considerations

Lon S. Schneider

4.3 Evaluation of the Healthcare Resource Utilization and Caregiver Time in Anti-dementia Drug Trials

A. Wimo, A.-L. Wetterholm, V. Masteg and B. Wipblad

4.4 Clinical and Economic Considerations of Anti-dementia Drug Treatment: Efficacy, Effectiveness, Efficiency

Howard Feldman and Bernard Prigent

4.5 Ethical Considerations in Pharmacoeconomic Trials in Dementia

Stephen G. Post

4.6 Issues in Cross-Cultural Assessment of Economic Outcomes in Dementia

Elke Witthaus

4.7 Nursing Home Placement and Mortality as Outcomes in Clinical Trials of Anti-dementia Drugs: Methodological Issues

S. Gracon and F. Smith

4.8 Outcomes Research and Alzheimer's Disease: A Pharmaceutical Industry Perspective

Vera Masteg

PART 5 FINAL REMARKS

5.1 A Proposed Health Economics Research Agenda for Dementia

Bengt Winblad, Göran Karlsson, Bengt Jönsson and Anders Wimo

Index